Nutromics received FDA breakthrough device designation for its wearable patch designed to monitor vancomycin drug levels in real time. The goal is to replace or reduce periodic blood draws used to dose vancomycin, a narrow therapeutic index antibiotic with dosing complexity. The device’s designation signals the FDA’s view that the technology could address a meaningful unmet need in antibiotic management—potentially improving dosing accuracy and patient outcomes while reducing clinician and lab burden. For the biotech ecosystem, the move also reflects a growing shift toward connected diagnostics and therapeutic drug monitoring, where continuous or near-real-time measurement can tighten dosing windows for drugs that are difficult to manage with intermittent sampling.